↓ Skip to main content

Guideline of transthyretin-related hereditary amyloidosis for clinicians

Overview of attention for article published in Orphanet Journal of Rare Diseases, February 2013
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#31 of 3,105)
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
11 news outlets
twitter
4 X users
patent
6 patents
wikipedia
3 Wikipedia pages

Citations

dimensions_citation
537 Dimensions

Readers on

mendeley
558 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Guideline of transthyretin-related hereditary amyloidosis for clinicians
Published in
Orphanet Journal of Rare Diseases, February 2013
DOI 10.1186/1750-1172-8-31
Pubmed ID
Authors

Yukio Ando, Teresa Coelho, John L Berk, Márcia Waddington Cruz, Bo-Göran Ericzon, Shu-ichi Ikeda, W David Lewis, Laura Obici, Violaine Planté-Bordeneuve, Claudio Rapezzi, Gerard Said, Fabrizio Salvi

Abstract

Transthyretin amyloidosis is a progressive and eventually fatal disease primarily characterized by sensory, motor, and autonomic neuropathy and/or cardiomyopathy. Given its phenotypic unpredictability and variability, transthyretin amyloidosis can be difficult to recognize and manage. Misdiagnosis is common, and patients may wait several years before accurate diagnosis, risking additional significant irreversible deterioration. This article aims to help physicians better understand transthyretin amyloidosis--and, specifically, familial amyloidotic polyneuropathy--so they can recognize and manage the disease more easily and discuss it with their patients. We provide guidance on making a definitive diagnosis, explain methods for disease staging and evaluation of disease progression, and discuss symptom mitigation and treatment strategies, including liver transplant and several pharmacotherapies that have shown promise in clinical trials.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 558 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 <1%
Portugal 2 <1%
Spain 1 <1%
Greece 1 <1%
Unknown 551 99%

Demographic breakdown

Readers by professional status Count As %
Other 84 15%
Researcher 65 12%
Student > Bachelor 60 11%
Student > Ph. D. Student 51 9%
Student > Master 51 9%
Other 96 17%
Unknown 151 27%
Readers by discipline Count As %
Medicine and Dentistry 177 32%
Biochemistry, Genetics and Molecular Biology 50 9%
Agricultural and Biological Sciences 39 7%
Pharmacology, Toxicology and Pharmaceutical Science 31 6%
Neuroscience 19 3%
Other 61 11%
Unknown 181 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 95. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 February 2023.
All research outputs
#442,762
of 25,373,627 outputs
Outputs from Orphanet Journal of Rare Diseases
#31
of 3,105 outputs
Outputs of similar age
#2,803
of 204,949 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#2
of 51 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,105 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 204,949 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.